A versatile framework for the design of ligand-dependent, transgene-specific transcription factors

Molecular Therapy

Volumn 3, Issue 2, 2001, Pages 262-273

  Xu, Ling ^a   Zerby, Dennis ^a   Huang, Ying ^a   Ji, Hong ^a   Nyanguile, Origeène F ^a   De Los Angeles, Joseph E ^a   Kadan, Michael J ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Adenovirus; Cysteine2 histidine2 zinc finger; Estrogen receptor; Gene therapy; Transgene

Indexed keywords

CYSTEINE; DNA BINDING PROTEIN; ESTROGEN RECEPTOR; HISTIDINE; LIGAND; STEROID RECEPTOR; TAMOXIFEN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR GAL 4; UNCLASSIFIED DRUG; ZINC FINGER PROTEIN;

ADENOVIRUS; ANIMAL EXPERIMENT; ARTICLE; CHIMERA; CONTROLLED STUDY; DNA BINDING; DNA SEQUENCE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; GENE CONTROL; GENE EXPRESSION REGULATION; GENE THERAPY; GENETIC ENGINEERING; IMMUNOGENICITY; IN VITRO STUDY; LIGAND BINDING; MALE; MOUSE; NONHUMAN; POINT MUTATION; PROTEIN DOMAIN; TRANSGENE; YEAST;

EID: 0034988731     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1006/mthe.2000.0254     Document Type: Article

References (56)

1. Gene therapy: The first decade
2. Adenovirus vectors for gene delivery
3. Adeno-associated virus-mediated gene delivery
4. High-capacity adenoviral vectors for gene transfer and somatic therapy
5. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease
6. Switching transgene expression in the brain using an adenoviral tetracycline-regulatable system
7. Regulation of gene expression in vivo following transduction by two separate rAAV vectors
8. Lentiviral vectors: Regulated gene expression
9. Regulated delivery of therapeutic proteins after in vivo somatic cell gene transfer
10. Long-term regulated expression of growth hormone in mice after intramuscular gene transfer
11. Adenovirus-mediated regulatable target gene expression in vivo
12. Adenovirus-mediated inducible gene expression in vivo by a hybrid ecdysone receptor
13. Modified steroid receptors and steroid-inducible promoters as genetic switches for gene therapy
14. The hormone-binding domains of the estrogen and glucocorticoid receptors contain an inducible transcription activation function
15. A selective transcriptional induction system for mammalian cells based on Gal4-estrogen receptor fusion proteins
16. A regulatory system for use in gene transfer
17. Ecdysone-inducible gene expression in mammalian cells and transgenic mice
18. Zinc fingers
19. The galvanization of biology: A growing appreciation for the roles of zinc
20. Zinc finger-DNA recognition: Crystal structure of a Zif268-DNA complex at 2.1A
21. Crystal structure of a five-finger GLI-DNA complex: New perspectives on zinc fingers
22. The crystal structure of a two zinc-finger peptide reveals an extension to the rules for zinc-finger/DNA recognition
23. In vivo repression by a site-specific DNA-binding protein designed against an oncogenic sequence
24. Building zinc fingers by selection: Toward a therapeutic application
25. Use of a zinc-finger consensus sequence framework and specificity rules to design specific DNA binding proteins
26. A general strategy for selecting high-affinity zinc finger proteins for diverse DNA target sites
27. Toward controlling gene expression at will: Selection and design of zinc-finger domains recognizing each of the 5′-GNN-3′ DNA target sequences
28. Transcriptional repression by zinc finger peptides
29. Getting a handhold on DNA: Design of poly-zinc finger proteins with femtomolar dissociation constants
30. Design of polydactyl zinc-finger proteins for unique addressing within complex genomes
31. Toward controlling gene expression at will: Specific regulation of the erbB-2/HER-2 promoter by using polydactyl zinc finger proteins constructed from modular building blocks
32. Positive and negative regulation of endogenous genes by designed transcription factors
33. The cloned human oestrogen receptor contains a mutation which alters its hormone binding properties
34. Tetracycline-controlled transcription in eukaryotes: Novel transactivators with graded transactivation potential
35. Parathyroid hormone responses of cyclic AMP-, serum- and phorbol ester-responsive reporter genes in osteoblast-like UMR-106 cells
36. Elimination of both E1 and E2a from adenovirus vectors further improves prospects for in vivo human gene therapy
37. Adenovirus mediated expression of therapeutic plasma levels of human factor IX in mice
38. Antiangiogenic gene therapy for cancer via systemic administration of adenoviral vectors expressing secretable endostatin
39. A high-efficiency Cre/loxP-based system for construction of adenoviral vectors
40. The estrogen receptor binds tightly to its responsive element as a ligand-induced homodimer
41. Molecular interactions of steroid hormone receptor with its enhancer element: Evidence for receptor dimer formation
42. Gene regulation by steroid hormones
43. Defining a minimal estrogen receptor DNA binding domain
44. Zinc fingers: Gilt by association
45. Solution structure of the DNA-binding domain of the oestrogen receptor
46. Beyond zinc fingers: Steroid hormone receptors have a novel structural motif for DNA recognition
47. Selective interaction of hsp90 with an estrogen receptor ligand-binding domain containing a point mutation
48. Identification of residues in the estrogen receptor that confer differential sensitivity to estrogen and hydroxytamoxifen
49. Ligand-activated site specific recombination in mice
50. Generation of estrogen receptor mutants with altered ligand specificity for use in establishing a regulatable gene expression system
51. Function of directly repeated half-sites as response elements for steroid hormone receptors
52. A modified oestrogen receptor ligand-binding domain as an improved switch for the regulation of heterologous proteins
53. Hormone-induced apoptosis by Fas-nuclear receptor fusion proteins: Novel biological tools for controlling apoptosis in vivo
54. Ligand-regulated site-specific recombination
55. Regulation of Cre recombinase activity by mutated estrogen receptor ligand-binding domains
56. Hormone-dependent transactivation by estrogen receptor chimeras that do not interact with hsp90